A new report paints a stark picture of how a subset of large healthcare providers is drawing the lion’s share of 340B savings within a single state. The controversial drug discount program has been ...

Add Yahoo as a preferred source to see more of our stories on Google. Photo: Shopify Partners / Burst (The Center Square) – Hospitals and clinics in Michigan participating in a federal drug discount ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare ...

Find the week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to provide ...

340B covered entities are expanding contracts with retail pharmacies that are increasingly located in counties with high rates of Medicare and Medicaid insurance coverage. The 340B Drug Pricing ...

The U.S. District Court for the District of Hawaii denied AstraZeneca’s request to block a state law protecting 340B contract pharmacy arrangements. In its ruling, issued Feb. 23, the court found that ...

While a federal judge squashed earlier plans for a 340B rebate pilot program, HHS appears poised to relaunch its attempts to transform the drug pricing program. Less than two weeks after the federal ...

Hospital groups are asking HHS to give stakeholders more time to weigh in on a potential overhaul of the 340B drug pricing program, warning that the current 30-day comment period isn’t sufficient to ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful. The 340B program ...